Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Agenus Inc. (NASDAQ: AGEN).

Full DD Report for AGEN

You must become a subscriber to view this report.


Recent News from (NASDAQ: AGEN)

Agenus to Present Clinical Data on Lead Programs at ASCO 2018
LEXINGTON, Mass. , May 17 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-...
Source: PR Newswire
Date: May, 17 2018 13:37
Agenus -6.5% on at-the-market sales deal for 20M shares
Biotech firm Agenus (NASDAQ: AGEN ) is 6.5% lower postmarket after a filing notes it's entered an at-the-market sales deal covering up to 20M shares. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 11 2018 17:56
Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update
Analysis focus: SGYP Synergy Pharma (SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investor s have taken up the cudgel against the management of Synergy. These investors have written to a nu...
Source: SeekingAlpha
Date: May, 08 2018 03:34
Agenus' (AGEN) CEO Garo Armen on Q1 2018 Results - Earnings Call Transcript
Agenus (AGEN) Q1 2018 Earnings Conference Call May 7, 2018, 11:00 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Christine Klaskin - VP of Finance Analysts Matt Philips - William Blair Presentation Operator ...
Source: SeekingAlpha
Date: May, 07 2018 14:54
Agenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston
LEXINGTON, Mass. , May 7 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Garo Armen , Ph.D., Chairman & CEO, and Jennifer Buell , Ph....
Source: PR Newswire
Date: May, 07 2018 13:00
Agenus reports Q1 results; provides milestones for 2018
Agenus ( AGEN ) Q1 results : R&D Expense: $29.4M (-9.8%); SG&A: $10.7M (-7.8%); Net Loss: ($54.3M); Loss Per Share: ($0.53); Quick Assets: $52.3M (-13.1%). More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: May, 07 2018 09:26
Agenus misses by $0.23
Agenus (NASDAQ: AGEN ): Q1 EPS of -$0.53 misses by $0.23 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 07 2018 09:07
Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update
LEXINGTON, Mass. , May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the first quarter end...
Source: PR Newswire
Date: May, 07 2018 09:00
Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast
LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its first quarter 2018 financial results before the market opens on Monday,...
Source: PR Newswire
Date: May, 03 2018 09:00
AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA
LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Andy Hurwitz , Vice President, Head o...
Source: PR Newswire
Date: May, 01 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-173.403.353.453.281,060,262
2017-06-203.503.863.983.502,703,624
2017-06-193.463.523.523.35749,490
2017-06-163.383.463.463.332,775,847
2017-06-153.453.403.4923.36666,546

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17282,870418,61067.5736Short
2018-08-16226,773461,30849.1587Short
2018-08-15343,025876,16839.1506Short
2018-08-14117,809343,86634.2601Cover
2018-08-13238,029415,17757.3319Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AGEN.


About Agenus Inc. (NASDAQ: AGEN)

Logo for Agenus Inc. (NASDAQ: AGEN)

Not available

 

Contact Information

 

 

Current Management

  • Garo H. Armen / President, CEO
  • Shalini Sharp / CFO
  • Jonae Barnes / IR

Current Share Structure

  • Market Cap: $343,565,270 - 05/14/2018
  • Issue and Outstanding: 102,556,797 - 02/28/2018

 


Recent Filings from (NASDAQ: AGEN)

Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 05 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: AGEN)

Daily Technical Chart for (NASDAQ: AGEN)


Stay tuned for daily updates and more on (NASDAQ: AGEN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AGEN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AGEN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AGEN and does not buy, sell, or trade any shares of AGEN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/